Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza: A Systematic Review and Meta-Analysis.

IF 9.7 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Jessie J Goldsmith, Sarah Tavlian, Christy Vu, Annette K Regan, Patricia Therese Campbell, Sheena G Sullivan
{"title":"Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza: A Systematic Review and Meta-Analysis.","authors":"Jessie J Goldsmith, Sarah Tavlian, Christy Vu, Annette K Regan, Patricia Therese Campbell, Sheena G Sullivan","doi":"10.1001/jamanetworkopen.2025.35250","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Based on the findings of immunogenicity studies, the World Health Organization has recommended influenza vaccine-naive children younger than 9 years receive 2 doses of influenza vaccine in the first year of vaccination.</p><p><strong>Objective: </strong>To estimate the increase in protection associated with the second dose of influenza vaccine for influenza vaccine-naive children younger than 9 years.</p><p><strong>Data sources: </strong>MEDLINE, EMBASE, and CINAHL were searched for articles published from inception to March 24, 2025.</p><p><strong>Study selection: </strong>Peer-reviewed studies that reported vaccine efficacy or vaccine effectiveness against influenza for influenza vaccine-naive children aged 6 months to younger than 9 years by dose number were included. Modeling and cost-effectiveness studies were excluded.</p><p><strong>Data extraction and synthesis: </strong>Two reviewers independently screened and extracted data and assessed studies' risk of bias. The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline.</p><p><strong>Main outcomes and measures: </strong>For studies reporting both 1 and 2 dose estimates, the difference in vaccine efficacy or effectiveness was calculated in order to estimate the additional protection associated with the second dose. Pooled vaccine efficacy or effectiveness and difference were calculated separately for inactivated influenza and live attenuated influenza vaccines.</p><p><strong>Results: </strong>There were 51 studies with 415 050 participants included in this analysis. The pooled absolute increase in vaccine effectiveness of a second inactivated influenza vaccine dose in the first year of vaccination was 15 percentage points (pp) (95% CI, -2.8 pp to 33 pp) for those younger than 9 years and 28 pp (95% CI, 4.7 pp to 51 pp) for children younger than 3 years. Insufficient estimates were available to assess the incremental benefit associated with a second dose of live attenuated influenza vaccine.</p><p><strong>Conclusions and relevance: </strong>In this systematic review and meta-analysis of influenza vaccine efficacy and effectiveness in the first year of vaccination, receiving 2 doses of inactivated influenza vaccine was associated with improved protection for children younger than 3 years compared with those who receive one dose; however, when the age range was broadened to younger than 9 years, the second dose of inactivated influenza vaccine was not significantly associated with increased protection. Additional high-quality studies are needed to assess the impact of the 2-dose schedule for both vaccine types by age to determine the age range for which a 2-dose schedule is beneficial.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 10","pages":"e2535250"},"PeriodicalIF":9.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495502/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Network Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamanetworkopen.2025.35250","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: Based on the findings of immunogenicity studies, the World Health Organization has recommended influenza vaccine-naive children younger than 9 years receive 2 doses of influenza vaccine in the first year of vaccination.

Objective: To estimate the increase in protection associated with the second dose of influenza vaccine for influenza vaccine-naive children younger than 9 years.

Data sources: MEDLINE, EMBASE, and CINAHL were searched for articles published from inception to March 24, 2025.

Study selection: Peer-reviewed studies that reported vaccine efficacy or vaccine effectiveness against influenza for influenza vaccine-naive children aged 6 months to younger than 9 years by dose number were included. Modeling and cost-effectiveness studies were excluded.

Data extraction and synthesis: Two reviewers independently screened and extracted data and assessed studies' risk of bias. The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline.

Main outcomes and measures: For studies reporting both 1 and 2 dose estimates, the difference in vaccine efficacy or effectiveness was calculated in order to estimate the additional protection associated with the second dose. Pooled vaccine efficacy or effectiveness and difference were calculated separately for inactivated influenza and live attenuated influenza vaccines.

Results: There were 51 studies with 415 050 participants included in this analysis. The pooled absolute increase in vaccine effectiveness of a second inactivated influenza vaccine dose in the first year of vaccination was 15 percentage points (pp) (95% CI, -2.8 pp to 33 pp) for those younger than 9 years and 28 pp (95% CI, 4.7 pp to 51 pp) for children younger than 3 years. Insufficient estimates were available to assess the incremental benefit associated with a second dose of live attenuated influenza vaccine.

Conclusions and relevance: In this systematic review and meta-analysis of influenza vaccine efficacy and effectiveness in the first year of vaccination, receiving 2 doses of inactivated influenza vaccine was associated with improved protection for children younger than 3 years compared with those who receive one dose; however, when the age range was broadened to younger than 9 years, the second dose of inactivated influenza vaccine was not significantly associated with increased protection. Additional high-quality studies are needed to assess the impact of the 2-dose schedule for both vaccine types by age to determine the age range for which a 2-dose schedule is beneficial.

第一季儿童接种流感疫苗2剂与1剂的比较:系统回顾和荟萃分析
重要性:根据免疫原性研究的结果,世界卫生组织建议9岁以下未接种流感疫苗的儿童在第一年接种两剂流感疫苗。目的:评估第二剂流感疫苗对9岁以下未接种流感疫苗的儿童的保护作用。数据来源:MEDLINE、EMBASE和CINAHL检索自建校至2025年3月24日发表的文章。研究选择:纳入了同行评审的研究,这些研究报告了疫苗对6个月至9岁以下未接种流感疫苗的儿童的有效性或疫苗对流感的有效性。模型和成本效益研究被排除在外。数据提取和综合:两名审稿人独立筛选和提取数据,并评估研究的偏倚风险。本研究遵循系统评价和荟萃分析首选报告项目(PRISMA)报告指南。主要结果和措施:对于报告1剂和2剂估计的研究,计算疫苗效力或有效性的差异,以便估计与第二次剂量相关的额外保护。分别计算灭活疫苗和减毒活疫苗的合并疫苗效力或有效性和差异。结果:共有51项研究,415 050名参与者纳入本分析。9岁以下儿童接种第一剂灭活疫苗后,疫苗有效性的绝对增加为15个百分点(95% CI, -2.8 - 33), 3岁以下儿童接种第二剂灭活疫苗后,疫苗有效性的绝对增加为28个百分点(95% CI, 4.7 - 51)。没有足够的估计来评估与第二剂减毒流感活疫苗相关的增量效益。结论和相关性:在这项关于流感疫苗接种第一年疗效和有效性的系统回顾和荟萃分析中,与接种一剂流感灭活疫苗的儿童相比,接种两剂流感灭活疫苗可改善对3岁以下儿童的保护;然而,当年龄范围扩大到9岁以下时,第二剂灭活流感疫苗与保护作用的增强没有显著关联。需要更多的高质量研究来评估两种疫苗类型按年龄划分的两剂方案的影响,以确定两剂方案有益的年龄范围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA Network Open
JAMA Network Open Medicine-General Medicine
CiteScore
16.00
自引率
2.90%
发文量
2126
审稿时长
16 weeks
期刊介绍: JAMA Network Open, a member of the esteemed JAMA Network, stands as an international, peer-reviewed, open-access general medical journal.The publication is dedicated to disseminating research across various health disciplines and countries, encompassing clinical care, innovation in health care, health policy, and global health. JAMA Network Open caters to clinicians, investigators, and policymakers, providing a platform for valuable insights and advancements in the medical field. As part of the JAMA Network, a consortium of peer-reviewed general medical and specialty publications, JAMA Network Open contributes to the collective knowledge and understanding within the medical community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信